RayzeBio also raised more funds in its stock sale than it had initially projected  a positive indicator for a queue of other young biotechs attempting to go public. The San Diegobased company is developing an experimental radiopharmaceutical drug called RYZ101 for neuroendocrine tumors. . The therapy which is aimed at the same target as Novartis approved medicine Lutathera entered Phase 3 testing in May